Literature DB >> 19542194

Clinical significance of bone alkaline phosphatase isoforms, including the novel B1x isoform, in mild to moderate chronic kidney disease.

Mathias Haarhaus1, Anders Fernström, Martin Magnusson, Per Magnusson.   

Abstract

BACKGROUND: Mineral bone disorder (MBD) is a common complication of chronic kidney disease (CKD) even during the early stages. Bone alkaline phosphatase (BALP) is a marker of bone formation and plays a pivotal role in the mineralization process. Three BALP isoforms (B/I, B1 and B2) have been identified in healthy individuals and a fourth isoform (B1x) has been discovered in serum from dialysis patients. We investigated these BALP isoforms, type I procollagen intact amino-terminal propeptide (PINP), carboxy-terminal telopeptide of type I collagen (CTX) and tartrate-resistant acid phosphatase isoform 5b (TRACP5b), as well as bone mineral density (BMD) in predialysis CKD patients.
METHODS: PINP, CTX, TRACP5b and BALP isoforms were analysed in serum from 46 patients within CKD stages 3-5. BMD was determined by dual-energy x-ray absorptiometry.
RESULTS: PINP, TRACP5b and the BALP isoforms, B/I, B1 and B2, were independent predictors of total hip BMD in all patients. Furthermore, B/I predicted osteopaenia in the hip and in the distal 1/3 of the radius in CKD stage 3. The B1x isoform was detected in nine patients (20%), who had lower GFR, higher phosphate and calcium x phosphate product.
CONCLUSION: We found an association of BALP isoforms and other markers of bone turnover with total hip BMD, which predominantly comprises trabecular bone. The association of the new BALP isoform B1x with risk factors for vascular calcification leads us to hypothesize a possible role for B1x in this process. The significance of the BALP isoforms in CKD remains to be further explored in experimental and clinical settings in conjunction with bone histomorphometry.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19542194     DOI: 10.1093/ndt/gfp300

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  9 in total

1.  Changes in bone mineral density following long-term simultaneous pancreas-kidney transplantation.

Authors:  Ana Rocha; La Salete Martins; Jorge Malheiro; Jorge Dores; Clara Santos; Castro Henriques
Journal:  J Bone Miner Metab       Date:  2015-04-03       Impact factor: 2.626

2.  Bone alkaline phosphatase isoforms in hemodialysis patients with low versus non-low bone turnover: a diagnostic test study.

Authors:  Mathias Haarhaus; Marie-Claude Monier-Faugere; Per Magnusson; Hartmut H Malluche
Journal:  Am J Kidney Dis       Date:  2015-04-02       Impact factor: 8.860

Review 3.  Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.

Authors:  P Szulc; K Naylor; N R Hoyle; R Eastell; E T Leary
Journal:  Osteoporos Int       Date:  2017-06-19       Impact factor: 4.507

Review 4.  Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD.

Authors:  Mathias Haarhaus; Vincent Brandenburg; Kamyar Kalantar-Zadeh; Peter Stenvinkel; Per Magnusson
Journal:  Nat Rev Nephrol       Date:  2017-05-15       Impact factor: 28.314

5.  Isozyme profile and tissue-origin of alkaline phosphatases in mouse serum.

Authors:  Cecilia Halling Linder; Ulrika H Englund; Sonoko Narisawa; José Luis Millán; Per Magnusson
Journal:  Bone       Date:  2013-01-10       Impact factor: 4.398

Review 6.  Bone Turnover Markers in Children: From Laboratory Challenges to Clinical Interpretation.

Authors:  Aurélie Ladang; Frank Rauch; Edgard Delvin; Etienne Cavalier
Journal:  Calcif Tissue Int       Date:  2022-03-04       Impact factor: 4.333

Review 7.  Alkaline Phosphatase: An Old Friend as Treatment Target for Cardiovascular and Mineral Bone Disorders in Chronic Kidney Disease.

Authors:  Mathias Haarhaus; Giuseppe Cianciolo; Simona Barbuto; Gaetano La Manna; Lorenzo Gasperoni; Giovanni Tripepi; Mario Plebani; Maria Fusaro; Per Magnusson
Journal:  Nutrients       Date:  2022-05-19       Impact factor: 6.706

Review 8.  Pharmacologic epigenetic modulators of alkaline phosphatase in chronic kidney disease.

Authors:  Mathias Haarhaus; Dean Gilham; Ewelina Kulikowski; Per Magnusson; Kamyar Kalantar-Zadeh
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-01       Impact factor: 3.416

9.  The Novel Bone Alkaline Phosphatase Isoform B1x Is Associated with Improved 5-Year Survival in Chronic Kidney Disease.

Authors:  Mathias Haarhaus; Anders Fernström; Abdul Rashid Qureshi; Per Magnusson
Journal:  Nutrients       Date:  2021-12-09       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.